July 31, 2018
Video
Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.
Zongertinib Elicits Responses in HER2-Mutant NSCLC
How an Advocate Unites Voices to Guide MPN Research Decisions
Healer, Mentor and Leader
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models